270032 VO Medizinische Radiochemie 2 (2020S)
Tracer Development - from Bench to Bed
Labels
Termine: 11 x 90 min Einheiten, Nuklearmedizin 3L, Bibliothek (AKH Hauptgebäude, Ebene 3, Raum jeweils um 16:30 bis 18 Uhr:
Do.05.03; Di.17.03; Do.19.03; Di.24.03; Do.26.03; Di. 31.03; Do. 02.04; Di. 21.04; Do. 23.04; Di. 28.04 & Do. 30.04
Vorlesungsfrei: (12.03; 06.04 bis 19.04)
Do.05.03; Di.17.03; Do.19.03; Di.24.03; Do.26.03; Di. 31.03; Do. 02.04; Di. 21.04; Do. 23.04; Di. 28.04 & Do. 30.04
Vorlesungsfrei: (12.03; 06.04 bis 19.04)
An/Abmeldung
Hinweis: Ihr Anmeldezeitpunkt innerhalb der Frist hat keine Auswirkungen auf die Platzvergabe (kein "first come, first served").
Details
Sprache: Deutsch
Prüfungstermine
Lehrende
Termine
Termine: 11 x 90 min Einheiten, Nuklearmedizin 3L, Bibliothek (AKH Hauptgebäude, Ebene 3, Raum jeweils um 16:30 bis 18 Uhr:
Do.05.03; Di.17.03; Do.19.03; Di.24.03; Do.26.03; Di. 31.03; Do. 02.04; Di. 21.04; Do. 23.04; Di. 28.04 & Do. 30.04
Vorlesungsfrei: (12.03; 06.04 bis 19.04)
Information
Ziele, Inhalte und Methode der Lehrveranstaltung
Art der Leistungskontrolle und erlaubte Hilfsmittel
Multiple Choice Test/Oniline Oral ExamDo, 7.5.20 16:30
Do, 14.5.20 16:30
Do, 25.6.20 16:30
Do, 14.5.20 16:30
Do, 25.6.20 16:30
Mindestanforderungen und Beurteilungsmaßstab
-To learn about the most important pharmacological criteria in radiopharmaceutical drug development
-To know the most important radiopharmaceuticals for nuclear medicine
-To hear about important methods in drug development
-To understand essentials in (radio)pharmacological behavior
-To understand the theranostic concept
-To understand preclinical and clinical study designs (development process)
-To know the most important radiopharmaceuticals for nuclear medicine
-To hear about important methods in drug development
-To understand essentials in (radio)pharmacological behavior
-To understand the theranostic concept
-To understand preclinical and clinical study designs (development process)
Prüfungsstoff
See above, minimum requirements and assessment criteria
Literatur
1. "Handbook of Radiopharmaceuticals" von Michael Welch und Carol S. Redvanly
2. "Radiopharmaceuticals: in Nuclear Pharmacy and Nuclear Medicine" von Richard J., Ph.D. Kowalsky, Steven W., Ph.D. Falen
3. . ETH ZÜRICH - RADIOPHARMAZEUTISCHE CHEMIE http://www.pharma.ethz.ch/institute_groups/radiopharmaceutical_science/lectures/index
4. Universität Würzburg - KURSUS DER NUKLEARMEDIZIN http://www.uni-wuerzbrug.de/nuklearmedizin/kursus/Kursus.htm
5. 5. The role of radiopharmaceuticals in drug discovery and development. Kairemo K. Curr Pharm Des. 2009;15(9):926-7
6. Molecular Imaging with PET. Ametamey S, Honer M, Schubiger PA, Chem. Rev. 2008, 108, 1501–1516
7. Animal Models for Human Cancer, Edited by Marianne I. Martic-Kehl and P. August Schubiger, Dicovery and Development of Novel Therapeutics, Volume 69
2. "Radiopharmaceuticals: in Nuclear Pharmacy and Nuclear Medicine" von Richard J., Ph.D. Kowalsky, Steven W., Ph.D. Falen
3. . ETH ZÜRICH - RADIOPHARMAZEUTISCHE CHEMIE http://www.pharma.ethz.ch/institute_groups/radiopharmaceutical_science/lectures/index
4. Universität Würzburg - KURSUS DER NUKLEARMEDIZIN http://www.uni-wuerzbrug.de/nuklearmedizin/kursus/Kursus.htm
5. 5. The role of radiopharmaceuticals in drug discovery and development. Kairemo K. Curr Pharm Des. 2009;15(9):926-7
6. Molecular Imaging with PET. Ametamey S, Honer M, Schubiger PA, Chem. Rev. 2008, 108, 1501–1516
7. Animal Models for Human Cancer, Edited by Marianne I. Martic-Kehl and P. August Schubiger, Dicovery and Development of Novel Therapeutics, Volume 69
Zuordnung im Vorlesungsverzeichnis
AC-4
Letzte Änderung: Mi 19.08.2020 07:49
-Pharmacokinetics and Modelling
-Special Challenges in neuro-radiopharmaceutical development (blood brain barrier)
- Methods of radiopharmaceutical drug development and process
-Radiopharmaceuticals for diagnostic, therapeutic use and developments in neuroimaging
-Preclinical studies (in vitro, animal studies) and clinical studies